| 0.1829 0 (0%) | 11-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Surgalign Holdings, Inc. is a global medical technology firm dedicated to the design, production, distribution, and marketing of spinal implants. Its comprehensive product line addresses various spinal procedures: for thoracolumbar surgeries, it offers systems like the Streamline TL Spinal Fixation for complex and degenerative conditions, and the Streamline MIS Spinal Fixation for minimally invasive approaches, alongside various interbody fusion devices. Cervical procedure solutions include the CervAlign ACP anterior cervical plate system, the Fortilink-C IBF system utilizing TETRAfuse 3D technology for cervical interbody fusion, and the Streamline OCT system for occipito-cervico-thoracic posterior spine applications. The company also provides motion preservation systems, such as the Coflex Interlaminar Stabilization device for moderate to severe lumbar spinal stenosis in conjunction with decompression, the HPS 2.0 Universal Fixation system for posterior stabilization of the thoracolumbar spine, and the SImmetry SI Joint Fusion system, a minimally invasive implant designed to decrease opioid reliance, discomfort, and functional impairment. Furthermore, Surgalign is developing an innovative digital surgery platform that incorporates Augmented Reality and Artificial Intelligence specifically for spinal procedures. Products are sold to hospitals, ambulatory surgery centers, and healthcare providers via both independent spine and biomaterial distributors and a direct sales team. Established in 1997, the company is headquartered in Deerfield, Illinois.
Tue, 19 May 2026
Surgalign Holdings stock (US87936R1068): what investors need to know after the Nasdaq delisting - AD HOC NEWS
Sun, 17 May 2026
Surgalign Holdings stock (US87936R1068): what the latest restructuring steps mean for shareholders - AD HOC NEWS
Sat, 25 Nov 2023
Surgalign Holdings Inc. (SRGA) Share Price Today | Surgalign Holdings (SRGA) Live NSE/BSE - Value Research
Fri, 23 Jun 2023
Surgalign (SRGA) Stock Rallied 96.2% Despite the Delisting Notice - AskTraders
Wed, 01 Mar 2023
Xtant Medical Acquires Coflex® Product Line from Surgalign for $17 Million - Ortho Spine News
Wed, 10 Aug 2022
Surgalign Announces Global Settlement Agreement with Resolve Surgical Technologies and RTI Surgical, Inc. - Ortho Spine News
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|